Calcium pyrophosphate deposition disease: clinical manifestations.
Calcium pyrophosphate deposition (CPPD) disease is an arthropathy caused by calcium pyrophosphate dihydrate (CPP) crystal deposits in articular tissues, most commonly fibrocartilage and hyaline cartilage. According to EULAR, four different clinical presentations can be observed: 1) asymptomatic CPPD; 2) osteoarthritis (OA) with CPPD; 3) acute CPP crystal arthritis; 4) chronic CPP inflammatory crystal arthritis. Acute CPP crystal arthritis is characterized by sudden onset of pain, swelling and tenderness with overlying erythema, usually in a large joint, most often the knee, wrist, shoulder, and hip. Occasionally, ligaments, tendons, bursae, bone and the spine can be involved. CPPD of the atlanto-occipital joint (crowned dens syndrome) can cause periodic acute cervico-occipital pain with fever, neck stiffness and laboratory inflammatory syndrome. Chronic inflammatory arthritis is characterized by joint swelling, morning stiffness, pain, and high ESR and CRP. The relationship between OA and CPPD is still unclear. The main problem is whether such crystals are directly involved in the pathogenesis of OA or if they are the result of joint degeneration. Diagnosis is based on evaluation of history and clinical features, conventional radiology, and synovial fluid examination. Non-polarized light microscopy should be used initially to screen for CPPD crystals based upon their characteristic morphology, and compensated polarized light microscopy, showing the crystals to be weakly positive birefringent, is recommended for definitive identification, although this last pattern only occurs in about 20% of samples. The main goals of CPPD therapy are control of the acute or chronic inflammatory reaction and prevention of further episodes.
Clinica Reumatologica, Dipartimento di Medicina Interna, Università di Genova, Italy.
C
C
Ferrone
R
R
Andracco
M A
MA
Cimmino
D001175:Arthrography; D015415:Biomarkers / Q000378:metabolism; D002131:Calcium Pyrophosphate / Q000378:metabolism*; D002805:Chondrocalcinosis / Q000175:diagnosis* / Q000000981:diagnostic imaging / Q000188:drug therapy / Q000378:metabolism; D003937:Diagnosis, Differential; D018450:Disease Progression; D006074:Gout Suppressants / Q000627:therapeutic use; D006801:Humans; D007596:Joints / Q000473:pathology; D008022:Ligaments / Q000473:pathology; D010003:Osteoarthritis / Q000175:diagnosis* / Q000000981:diagnostic imaging / Q000188:drug therapy / Q000378:metabolism; D012307:Risk Factors; D013131:Spine / Q000473:pathology; D013582:Synovial Fluid / Q000378:metabolism; D013710:Tendons / Q000473:pathology
D015415:Biomarkers; D006074:Gout Suppressants; D002131:Calcium Pyrophosphate